First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: Updated results from the German HIV-1 seroconverter study

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zu Knyphausen, Fabia ^a   Scheufele, Ramona ^b   Kücherer, Claudia ^b   Jansen, Klaus ^b   Somogyi, Sybille ^b   Dupke, Stephan ^c   Jessen, Heiko ^d   Schürmann, Dirk ^a   Hamouda, Osamah ^b   Meixenberger, Karolin ^b   Bartmeyer, Barbara ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Medical Care Centre Driesener Strasse   (Germany)

^d Medical Care Centre Jessen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALGORITHM; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; ETHNIC GROUP; FEMALE; GENE MUTATION; GENOTYPE; GERMAN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SEROCONVERSION; TREATMENT RESPONSE; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84900399715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095956     Document Type: Article

References (67)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. (Pubitemid 28135961)
2. Jacobson MA, French M (1998) Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 12 Suppl A: S157-163.
3. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, et al. (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135: 17-26. (Pubitemid 32619279)
4. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, et al. (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24: 123-137.
5. Booth CL, Geretti AM (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056. (Pubitemid 47073314)
6. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, et al. (2009) Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23: 717-724.
7. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, et al. (2004) Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 18: 1571-1577. (Pubitemid 39037481)
8. Balotta C, Berlusconi A, Pan A, Violin M, Riva C, et al. (2000) Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 5: 7-14. (Pubitemid 30261199)
9. Babic DZ, Seme K, Tomazic J, Vidmar L, Poljak M (2006) HIV-1 subtype B epidemic and transmission patterns in Slovenia. Coll Antropol 30 Suppl 2: 25-31.
10. de Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V (2002) Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 16: 1830-1832.
11. de Mendoza C, Garrido C, Corral A, Ramirez-Olivencia G, Jimenez-Nacher I, et al. (2007) Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses 23: 879-885. (Pubitemid 47267494)
12. Descamps D, Chaix ML, Andre P, Brodard V, Cottalorda J, et al. (2005) French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 38: 545-552. (Pubitemid 40524476)
13. Garcia F, Perez-Cachafeiro S, Guillot V, Alvarez M, Perez-Romero P, et al. (2011) Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naive HIV-infected individuals (CoRIS). Antiviral Res 91: 150-153.
14. Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al. (2007) [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]. Dtsch Med Wochenschr 132: 977-982.
15. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, et al. (2006) Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41: 573-581.
16. Paraskevis D, Magiorkinis E, Katsoulidou A, Hatzitheodorou E, Antoniadou A, et al. (2005) Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 112: 115-122. (Pubitemid 40966783)
17. Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, et al. (2008) Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 62: 464-468.
18. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, et al. (2007) Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 8: 511-519. (Pubitemid 47616830)
19. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, et al. (2007) Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848. (Pubitemid 47434265)
20. SPREAD (2008) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22: 625-635.
21. Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, et al. (2008) Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 24: 355-362. (Pubitemid 351457751)
22. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
23. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, et al. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-2229. (Pubitemid 350287221)
24. Group UC (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21: 1035-1039.
25. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192: 958-966. (Pubitemid 41266791)
26. Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, et al. (2012) Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 7: e33484.
27. Yebra G, de Mulder M, Perez-Elias MJ, Perez-Molina JA, Galan JC, et al. (2011) Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One 6: e26757.
28. Geretti AM (2007) Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 20: 22-32.
29. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, et al. (2012) Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect.
30. Lohse N, Obel N, Kronborg G, Jorgensen LB, Pedersen C, et al. (2006) Declining prevalence of HIV-infected individuals at risk of transmitting drugresistant HIV in Denmark during 1997-2004. Antivir Ther 11: 591-600. (Pubitemid 44277424)
31. Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, et al. (2013) National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother.
32. (11/2012) Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health - HIV/AIDS. Epidemiologisches Bulletin 47.
33. Bansi L, Geretti AM, Dunn D, Hill T, Green H, et al. (2010) Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr 53: 633-639.
34. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371.
35. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-188. (Pubitemid 34755278)
36. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, et al. (2007) Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 12: 1305-1310.
37. Shet A, Berry L, Mohri H, Mehandru S, Chung C, et al. (2006) Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 41: 439-446.
38. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394. (Pubitemid 34851830)
39. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort. PLoS ONE 5: e12718.
40. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, et al. (2001) Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26: 266-273. (Pubitemid 32246557)
41. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, et al. (1999) Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 13: 71-80. (Pubitemid 29308516)
42. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
43. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21: 6-14.
44. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800. (Pubitemid 41535530)
45. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, et al. (2005) Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 41: 1350-1354. (Pubitemid 41532683)
46. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, et al. (2008) Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 48: 324-333.
47. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, et al. (2005) Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331: 1368.
48. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000.
49. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, et al. (1998) Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 72: 3520-3523. (Pubitemid 28188646)
50. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, et al. (2003) Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37: 1693-1698. (Pubitemid 37549958)
51. Turner D, Brenner B, Routy JP, Moisi D, Rosberger Z, et al. (2004) Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr 37: 1627-1631. (Pubitemid 39658205)
52. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, et al. (2004) Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18: 1653-1660. (Pubitemid 39095782)
53. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, et al. (2007) Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167: 1782-1790. (Pubitemid 47403067)
54. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480. (Pubitemid 32164898)
55. Jakobsen MR, Tolstrup M, Sogaard OS, Jorgensen LB, Gorry PR, et al. (2010) Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 50: 566-573.
56. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
57. AIDS-Gesellschaft D (März 2010) "Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion".
58. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106. (Pubitemid 351679596)
59. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, et al. (2008) British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 9: 563-608.
60. Hoffmann C (2013) "Antiretrovirale Therapie" aus HIV 2011. Herausgeber Christian Hoffmann, Jürgen Rockstroh, erschienen im Medizin Fokus Verlag, Hamburg.
61. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 48: 239-247.
62. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199: 693-701.
63. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
64. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22: 1417-1423.
65. Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, et al. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22: 497-501. (Pubitemid 351317291)
66. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335.
67. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, et al. (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201: 662-671.